Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment

Katherine B. D'Antonio, Lucianna Schultz, Roula Albadine, Alison M. Mondul, Elizabeth A Platz, George J. Netto, Robert H. Getzenberg

Research output: Contribution to journalArticle

Abstract

Purpose: Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previous studies have suggested that Cyr61 may be a marker for a more aggressive phenotype. In this study, we evaluated the association between Cyr61 staining intensity and subsequent recurrence after surgical treatment of clinically localized prostate cancer. Experimental Design: A study of 229 men with recurrence and 229 controls matched on age, race, pathologic stage, and Gleason sum nested in a cohort of men who underwent radical prostatectomy for clinically localized prostate cancer, utilizing immunohistochemistry analysis of tissue microarray (TMA) sections, was conducted. Odds ratios (OR) of recurrence and 95% confidence intervals (CIs) were estimated using conditional logistic regression. Results: Recurrence was identified in 12.2% of cases, and in 24.0% of controls that had at least 1 TMA spot containing cancer with a staining intensity of 3 (P = 0.001). Taking into account age, pathologic stage and grade, presurgery prostate-specific antigen concentration, and calendar of surgery as a measure of tissue block storage time, men with a Cyr61 staining intensity of 3 were 56% less likely to recur than men with a lower staining intensity (OR = 0.44, 95% CI = 0.22-0.90). Conclusions: High Cyr61 staining intensity in adenocarcinoma was associated with a lower risk of recurrence after surgical treatment of prostate cancer independent of pathologic tumor characteristics. If validated in other sample sets, Cyr61 may serve as a tissue biomarker for stratifying men for risk of recurrence and thus could inform treatment decision making.

Original languageEnglish (US)
Pages (from-to)5908-5913
Number of pages6
JournalClinical Cancer Research
Volume16
Issue number23
DOIs
StatePublished - Dec 1 2010

Fingerprint

Prostatic Neoplasms
Recurrence
Staining and Labeling
Therapeutics
Odds Ratio
Tissue Array Analysis
Confidence Intervals
Extracellular Matrix Proteins
Prostate-Specific Antigen
Prostatectomy
Growth Hormone
Cysteine
Neoplasms
Intercellular Signaling Peptides and Proteins
Decision Making
Adenocarcinoma
Research Design
Biomarkers
Logistic Models
Immunohistochemistry

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

D'Antonio, K. B., Schultz, L., Albadine, R., Mondul, A. M., Platz, E. A., Netto, G. J., & Getzenberg, R. H. (2010). Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. Clinical Cancer Research, 16(23), 5908-5913. https://doi.org/10.1158/1078-0432.CCR-10-1200

Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. / D'Antonio, Katherine B.; Schultz, Lucianna; Albadine, Roula; Mondul, Alison M.; Platz, Elizabeth A; Netto, George J.; Getzenberg, Robert H.

In: Clinical Cancer Research, Vol. 16, No. 23, 01.12.2010, p. 5908-5913.

Research output: Contribution to journalArticle

D'Antonio, KB, Schultz, L, Albadine, R, Mondul, AM, Platz, EA, Netto, GJ & Getzenberg, RH 2010, 'Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment', Clinical Cancer Research, vol. 16, no. 23, pp. 5908-5913. https://doi.org/10.1158/1078-0432.CCR-10-1200
D'Antonio, Katherine B. ; Schultz, Lucianna ; Albadine, Roula ; Mondul, Alison M. ; Platz, Elizabeth A ; Netto, George J. ; Getzenberg, Robert H. / Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment. In: Clinical Cancer Research. 2010 ; Vol. 16, No. 23. pp. 5908-5913.
@article{f89d2b182bfa430d909a58b308ee41cd,
title = "Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment",
abstract = "Purpose: Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previous studies have suggested that Cyr61 may be a marker for a more aggressive phenotype. In this study, we evaluated the association between Cyr61 staining intensity and subsequent recurrence after surgical treatment of clinically localized prostate cancer. Experimental Design: A study of 229 men with recurrence and 229 controls matched on age, race, pathologic stage, and Gleason sum nested in a cohort of men who underwent radical prostatectomy for clinically localized prostate cancer, utilizing immunohistochemistry analysis of tissue microarray (TMA) sections, was conducted. Odds ratios (OR) of recurrence and 95{\%} confidence intervals (CIs) were estimated using conditional logistic regression. Results: Recurrence was identified in 12.2{\%} of cases, and in 24.0{\%} of controls that had at least 1 TMA spot containing cancer with a staining intensity of 3 (P = 0.001). Taking into account age, pathologic stage and grade, presurgery prostate-specific antigen concentration, and calendar of surgery as a measure of tissue block storage time, men with a Cyr61 staining intensity of 3 were 56{\%} less likely to recur than men with a lower staining intensity (OR = 0.44, 95{\%} CI = 0.22-0.90). Conclusions: High Cyr61 staining intensity in adenocarcinoma was associated with a lower risk of recurrence after surgical treatment of prostate cancer independent of pathologic tumor characteristics. If validated in other sample sets, Cyr61 may serve as a tissue biomarker for stratifying men for risk of recurrence and thus could inform treatment decision making.",
author = "D'Antonio, {Katherine B.} and Lucianna Schultz and Roula Albadine and Mondul, {Alison M.} and Platz, {Elizabeth A} and Netto, {George J.} and Getzenberg, {Robert H.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1158/1078-0432.CCR-10-1200",
language = "English (US)",
volume = "16",
pages = "5908--5913",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Decreased expression of Cyr61 is associated with prostate cancer recurrence after surgical treatment

AU - D'Antonio, Katherine B.

AU - Schultz, Lucianna

AU - Albadine, Roula

AU - Mondul, Alison M.

AU - Platz, Elizabeth A

AU - Netto, George J.

AU - Getzenberg, Robert H.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Purpose: Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previous studies have suggested that Cyr61 may be a marker for a more aggressive phenotype. In this study, we evaluated the association between Cyr61 staining intensity and subsequent recurrence after surgical treatment of clinically localized prostate cancer. Experimental Design: A study of 229 men with recurrence and 229 controls matched on age, race, pathologic stage, and Gleason sum nested in a cohort of men who underwent radical prostatectomy for clinically localized prostate cancer, utilizing immunohistochemistry analysis of tissue microarray (TMA) sections, was conducted. Odds ratios (OR) of recurrence and 95% confidence intervals (CIs) were estimated using conditional logistic regression. Results: Recurrence was identified in 12.2% of cases, and in 24.0% of controls that had at least 1 TMA spot containing cancer with a staining intensity of 3 (P = 0.001). Taking into account age, pathologic stage and grade, presurgery prostate-specific antigen concentration, and calendar of surgery as a measure of tissue block storage time, men with a Cyr61 staining intensity of 3 were 56% less likely to recur than men with a lower staining intensity (OR = 0.44, 95% CI = 0.22-0.90). Conclusions: High Cyr61 staining intensity in adenocarcinoma was associated with a lower risk of recurrence after surgical treatment of prostate cancer independent of pathologic tumor characteristics. If validated in other sample sets, Cyr61 may serve as a tissue biomarker for stratifying men for risk of recurrence and thus could inform treatment decision making.

AB - Purpose: Cysteine-rich angiogenic inducer 61 (Cyr61) is an extracellular matrix protein involved in the transduction of growth factor and hormone signaling. Previous studies have suggested that Cyr61 may be a marker for a more aggressive phenotype. In this study, we evaluated the association between Cyr61 staining intensity and subsequent recurrence after surgical treatment of clinically localized prostate cancer. Experimental Design: A study of 229 men with recurrence and 229 controls matched on age, race, pathologic stage, and Gleason sum nested in a cohort of men who underwent radical prostatectomy for clinically localized prostate cancer, utilizing immunohistochemistry analysis of tissue microarray (TMA) sections, was conducted. Odds ratios (OR) of recurrence and 95% confidence intervals (CIs) were estimated using conditional logistic regression. Results: Recurrence was identified in 12.2% of cases, and in 24.0% of controls that had at least 1 TMA spot containing cancer with a staining intensity of 3 (P = 0.001). Taking into account age, pathologic stage and grade, presurgery prostate-specific antigen concentration, and calendar of surgery as a measure of tissue block storage time, men with a Cyr61 staining intensity of 3 were 56% less likely to recur than men with a lower staining intensity (OR = 0.44, 95% CI = 0.22-0.90). Conclusions: High Cyr61 staining intensity in adenocarcinoma was associated with a lower risk of recurrence after surgical treatment of prostate cancer independent of pathologic tumor characteristics. If validated in other sample sets, Cyr61 may serve as a tissue biomarker for stratifying men for risk of recurrence and thus could inform treatment decision making.

UR - http://www.scopus.com/inward/record.url?scp=78650356981&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650356981&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-10-1200

DO - 10.1158/1078-0432.CCR-10-1200

M3 - Article

VL - 16

SP - 5908

EP - 5913

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 23

ER -